Trials / Completed
CompletedNCT01035580
Trial on Safety and Pharmacokinetics of Intravaginal Curcumin
Phase I Trial on Safety and Pharmacokinetics of Intravaginal Curcumin in Normal Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Emory University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to determine the maximum tolerable dose and safety of intravaginal curcumin in a normal population of women (women with no evidence of cervical cytological abnormalities by pap testing).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Curcumin | Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg |
| DRUG | curcumin | all patients received the drug |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-04-01
- Completion
- 2012-01-01
- First posted
- 2009-12-18
- Last updated
- 2013-11-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01035580. Inclusion in this directory is not an endorsement.